Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Sexually Transmitted Diseases 1Papillomavirus Infections 1Lung Neoplasms 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 11Vaccines, Synthetic 10Papillomavirus Vaccines 5Vaccines 3Imiquimod 3Gels 3green tea extract polyphenone E 2Duration of Therapy 2ranpirnase 1polyphenon E 1berdazimer sodium 1Viusid 1VP-102 1Therapies, Investigational 1Tea 1Omiganan 1Ointments 1GS-9191 1Cidofovir 1Cantharidin 13-ingenyl angelate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Condylomata Acuminata × ranpirnase × Clear all
NCT02535104 2018-06-06

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Tamir Biotechnology, Inc.

Phase 1/2 Completed
70 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡